1 Contribution of *de novo* retroelements to birth defects and childhood cancers

2

4

6

8

3 Chong Chu¹, Viktor Ljungström¹, Antuan Tran¹, Hu Jin¹, Peter J. Park^{1*}

- ⁵ ¹ Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA
- 7 * Correspondence should be addressed to P.J.P. (peter_park@hms.harvard.edu)
- 9 Abstract

10 Insertion of active retroelements—L1s, Alus, and SVAs—can disrupt proper genome function 11 and lead to various disorders including cancer. However, the role of *de novo* retroelements 12 (DNRTs) in birth defects and childhood cancers has not been well characterized due to the lack 13 of adequate data and efficient computational tools. Here, we examine whole-genome sequencing 14 data of 3,244 trios from 12 birth defect and childhood cancer cohorts in the Gabriella Miller Kids 15 First Pediatric Research Program. Using an improved version of our tool xTea (x-Transposable 16 element analyzer) that incorporates a deep-learning module, we identified 162 DNRTs, as well 17 as 2 pseudogene insertions. Several variants are likely to be causal, such as a *de novo Alu* 18 insertion that led to the ablation of a whole exon in the NF1 gene in a proband with brain tumor. 19 We observe a high *de novo* SVA insertion burden in both high-intolerance loss-of-function genes 20 and exons as well as more frequent de novo Alu insertions of paternal origin. We also identify 21 potential mosaic DNRTs from embryonic stages. Our study reveals the important roles of 22 DNRTs in causing birth defects and predisposition to childhood cancers. 23

25 INTRODUCTION

26 Three types of retroelements are still active in the human genome: long interspersed element-1 27 (L1), Alu, and SINE-VNTR-Alu (SVA). These retroelements replicate through RNA 28 intermediates by a "copy and paste" mechanism mediated by the LINE-1-encoded proteins; the 29 L1 machinery can also mediate retroduplication of protein-coding genes to generate processed 30 pseudogenes (PPGs). Retroelement insertions into genes may disrupt the function of the gene, 31 potentially leading to a wide spectrum of diseases (Hancks and Kazazian 2016; Burns 2017; 32 Chuong et al. 2017). In particular, de novo retroelement (DNRT) insertions have been associated 33 with several developmental disorders and other genetic diseases (Gardner et al. 2019; Brandler et 34 al. 2016; Brandler et al. 2018; Werling et al. 2018; Borges-Monroy et al. 2021). Such DNRT 35 insertions may occur in the gonadal tissues, resulting in a heterozygous germline variant in the 36 proband, or during embryonic development, resulting in a mosaic variant in the proband. 37

38 Compared to other types of *de novo* mutations, DNRTs have been less well studied due to (*i*) a 39 lack of large whole-genome sequencing (WGS) datasets (especially trios, which are critical for 40 accurately finding *de novo* insertions), and (*ii*) a lack of reliable computational methods designed 41 specifically for DNRTs. Although several tools have been developed for identifying germline 42 (Gardner et al. 2017; Keane et al. 2013; Thung et al. 2014; Zhuang et al. 2014) and somatic (Lee 43 et al. 2012; Tubio et al. 2014) retroelement insertions, they typically give many high false 44 positive calls for DNRTs because of the low rate of DNRTs and the low variant allele frequency 45 (VAF) of mosaic events. For trio data, one could treat a trio as two pairs of case-control samples and find events that exist in the proband but are absent in both parents; however, we find that a 46

47 more sensitive detection requires more sophisticated filtering steps specifically designed for the48 trio design.

49

50	Here, we extend our xTea (Chu et al. 2021) pipeline for <i>de novo</i> retroelement insertion
51	identification by further integrating a newly developed machine learning based filtering module.
52	We apply our pipeline to 3,244 trios from the Gabriella Miller Kids First Pediatric Research
53	Program (GMKF) composed of 12 cohorts of different birth defects and childhood cancers, as
54	well as 596 trios from the 1000 Genomes Project (Byrska-Bishop et al. 2022) as reference (Tab.
55	S1). We identified 162 DNRTs from the GMKF cohorts, several of which mobilized to genes
56	where disruptive variants previously have been deemed causative for the diseases. Below, we
57	describe several analyses including detailed examination of likely pathogenic insertions, trio-
58	based phasing to determine whether paternal and maternal contributions are equal, identification
59	of mosaic insertions that occurred at early embryonic stages and PPG insertions, characterization
60	of genes with a higher burden of insertions, and the activity of different SVA subfamilies.

62 **RESULTS**

63 De novo retroelements identification in Kids First and 1KGP data

64 We built an efficient pipeline for DNRT identification (Fig. 1a). Given trio data, we first run the 65 xTea germline module on the proband to identify a set of initial candidates. Because many of the 66 *de novo* events are potentially mosaic events in the proband with low VAFs, we set lenient 67 criteria including on the VAF threshold to ensure high sensitivity. Next, we run the xTea somatic 68 module on the initial candidates with each of the parents as a control. The output from this step 69 still has a high fraction of false positives due to the low cutoff settings. Thus, we apply two 70 additional filtering steps. First, we convert the *de novo* insertion identification problem to an 71 image classification problem by training a machine learning model based on training data labeled 72 from both real and simulated data (see Methods for details). Second, we manually inspect the 73 candidates to curate the final set of DNRTs. Combining the low cutoffs with the filtering steps 74 allows us to design a pipeline with both high sensitivity and high specificity, while its efficient 75 implementation enables application on large cohorts.

76

77 We ran our pipeline on 12 GMKF cohorts (Fig. 1b), totaling 3,244 WGS trios (Tab. S1). Across 78 all cohorts, we identified 162 DNRTs, including 95 Alu, 30 L1, 35 SVA, and 2 PPG insertions 79 (Tab. S2). Fig. 1c shows the number of DNRTs identified from each cohort by repeat type. 80 Besides the classic Alu, L1, and SVA insertions, we also identified 1 Alu-promoted deletion and 81 2 PPG insertions from 3 different cohorts. Of the 162 *de novo* insertions, 7 (4 Alu and 3 SVA) 82 are exonic, 2 Alu affect UTRs, 3 Alu are within promoter regions, and 6 (4 Alu, 1 L1, and 1 83 SVA) fall in enhancer regions. Among the others, 33 Alu, 12 L1 and 15 SVA are intronic and the 84 rest are intergenic (Fig. 1d). We also analyzed the recently-released trio data from the 1000

85	Genomes Project (1KGP) consisting of 603 trios of which 596 were successfully processed,
86	leading to identification of 26 Alu, 12 L1, and 8 SVA DNRTs (Tab. S3).
87	
88	We identified 9 and 0 exonic/UTR DNRTs from the GMKF (3,244 births) and 1KGP (596
89	births) cohorts, respectively. In comparison, the Deciphering Developmental Disorders (DDD)
90	study (Gardner et al. 2019) revealed 6 exonic/UTR variants in 9,738 births analyzed with whole-
91	exome sequencing (WES); another study (Borges-Monroy et al. 2021) of autism spectrum
92	disorder (ASD) showed 5 exonic/UTR variants in 4,184 births (Tab. S4). Thus, the exonic
93	(including UTR) <i>de novo</i> rate from the GMKF cohorts in this study is $4.5 \times (0.0027 \text{ vs } 0.0006)$
94	and $2.25 \times (0.0027 \text{ vs } 0.0012)$ higher than in the DDD and ASD studies, respectively. An earlier
95	systematical study on DDD (Deciphering Developmental Disorders Study, 2017) has shown that
96	developmental disorders have higher de novo mutation rate than autism, which is concordant
97	with the much higher rate in the GMKF study than in the ASD study. The much lower rate of the
98	DDD study may be due to the difference in the cohorts or possibly due to the lower sensitivity of
99	the method they used.



100

101 Fig. 1: Overview of the pipeline and identified *de novo* retroelements. a Schematic outline of 102 the upgraded xTea workflow. The proband sample from trio data is analyzed using the germline 103 module with low cutoffs and subsequently filtered using the somatic module and incorporating 104 parental data to identify candidate de novo events. A transfer learning based filtering step 105 following a manual inspection step is applied to filter out the false positives. **b** We ran our 106 pipeline on 3,244 trios from 12 disease cohorts released by the GMKF studies and identified 162 107 de novo retroelements. c The number of identified de novo retroelements by cohorts and repeat 108 types. Besides the classical TE insertions, we also identified 1 Alu promoted deletion and 2 109 pseudogene insertions from 3 different cohorts. d 7 (4 Alu and 3 SVA), 2 (Alu), 3 (Alu), and 6 (4 110 Alu, 1 L1 and 1 SVA) de novo retroelements fell in exons, UTRs, promoters, and enhancers 111 respectively. Out of the rest, 33 Alu, 12 L1, 15 SVA and 1 pseudogene are intronic insertions, and the remaining are all intergenic ones. e The exonic/UTR de novo rate from the GMKF and 112

113 1KGP cohorts (this study) compared to the Deciphering Developmental Disorders (DDD) study

114 and a study of autism spectrum disorders (ASD).

115 Potentially pathogenic *de novo* retroelement insertions

116 WGS data on trios provide an opportunity to identify pathogenic mutations and discover novel 117 disease-associated genes. We prioritized the identified 162 DNRTs by checking whether they 118 occur in (i) exonic or UTR regions; (ii) promoter or enhancer regions, as annotated in 119 ANNOVAR (Yang and Wang 2015); (iii) genes that are associated with the disease. In addition, 120 to account for potential compound heterozygosity, we also checked whether there are detectable 121 second hits for those DNRTs that fall in autosomal recessive genes. In Table 1, we show the 122 selected exonic, UTR, and other potentially pathogenic DNRTs and their annotations. 123 124 We identified two *Alu* insertions that fall in the exonic regions of *NF1*. One insertion promoted 125 an 8,758 bp deletion (chr17:31159322-31168079 on hg38) spanning all of exon 4 (Fig. 2a). The 126 polyA reads at the breakpoints, discordant pairs, and the copy number change strongly support 127 the existence of this complex event. Trio-based phasing and the high VAF indicates this complex 128 event is inherited from the father (a mosaic mutation in the father), but we cannot rule out the 129 possibility that this is an early embryonic event (a mosaic mutation in the child). The other Alu 130 insertion was mobilized to the 24th exon of NF1. Fig. 2b shows the clipped reads, polyA tail, and 131 the discordant reads present in the proband but absent in the parents. Both probands presented 132 with brain tumor and, since neurofibromatosis type 1 caused by a mutation in NF1 is an 133 autosomal dominant disorder associated with brain tumor, we propose these two exonic *de novo* 134 Alu insertions to be causal mutations. Besides the NFI cases, we also identified one SVA 135 insertion mobilized into an exon of the TRRAP gene in one proband who was diagnosed with 136 Ptosis (HP:0000508) within the Syndromic Cranial Dysinnervation (SCD) cohort. There have 137 been several reports demonstrating that variants in TRRAP are causative for several 138 developmental diseases including autism and syndromic intellectual disability (Cogné et al.

139	2019; Xia et al. 2019; Mavros et al. 2018), although no directly related cases have been reported
140	for SCD. In addition, we also identified one de novo Alu insertion in the 3' UTR region of
141	RREB1 in one proband with Ewing Sarcoma. The RREB1 gene has been associated with Ewing
142	Sarcoma in several of the earlier studies (Shi et al. 2020; Machiela et al. 2018).
143	
144	Although it is more challenging to functionally annotate the intronic DNRTs, we identified two
145	cases with variants that have a high chance of explaining the phenotype observed in the proband.
146	One case is a full length de novo L1 insertion mobilized in the sense orientation to the intron of
147	LTBP1. The patient was diagnosed with congenital diaphragmatic hernia (CDH)
148	(MONDO:0005711). The LTBP gene family has been demonstrated to be highly associated with
149	cutis laxa (a connective tissue disorder; Latin for loose skin) in several studies and the disorder is
150	linked to an increased risk of CDH (Bultmann-Mellin et al. 2015; Zhang et al. 2020; Pottie et al.
151	2021; Urban and Davis 2014). Since most types of cutis laxa are autosomal recessive, we further
152	screened for other types of mutations in the gene and detected one exonic deleterious SNP (2-
153	33567971-C-T; hg38). The SNP is a rare mutation with a population allelic frequency of $\sim 0.78\%$
154	in the gnomAD database (Chen et al. 2022). We therefore infer that the <i>de novo</i> L1 insertion and
155	the SNV lead to a compound heterozygous state resulting in CDH, although functional studies
156	are needed for validation. The other case is a <i>de novo Alu</i> insertion identified in a patient
157	diagnosed with right aortic arch (MONDO:0020417). The insertion mobilized to a strong
158	intronic enhancer of the gene NEK1. An on-going study (manuscript in preparation) shows that
159	variants in NEK1 are associated with congenital heart defect (CHD) in an autosomal dominant
160	pattern.
1.61	





163 Fig. 2: Two exonic *de novo* Alu insertions identified on NF1 gene. a An Alu insertion

164 promoted deletion was identified in one trio. The deletion spans 8,758bp and the two breakpoints

165 fell in intron 3 and 4 leading to deletion of the exon of number 4 of *NF1*. The copy number

166 change in the proband shows the existence of the deletion. The clipped reads, polyA reads, and

167 the discordant reads indicate the existence of an Alu insertion. Together, all these features

demonstrate the existence of the *Alu* insertion promoted deletion. **b** In another trio, one *NF1* exonic *Alu* insertion was identified in proband but absent from parents. Similarly, the clipped

reads, polyA reads and discordant pairs strongly support the presence of an *Alu* insertion.

Cohort	Proband	Repeat	Position	Region	Gene	pLI
CDH	PT_0MDDJ6T0	SVA	chr19:47152964	Exon	SAE1	0.989
CDH	PT_0XTN2CCZ	SVA	chr15:75648240	Exon	IMP3	5.333E-05
ODE	PT_PNVAXZ9A	Alu	chr2:19931364	Exon	WDR35	2.648E-16
ODE	PT_ZV2GG6F2	Alu	chr1:78643160	Exon	IFI44L	2.218E-10
SCD	PT_BGKBJ0JS	SVA	chr7:98892523	Exon	TRRAP	1.0
CCBD	PT MYK8V1XH	Alu promoted deletion	chr17:31159322- 31168079	Exon	NFI	1.0
CCBD	PT 8B6VTS55	Alu	chr17:31230309	Exon	NF1	1.0
ES	PT 469265KR	Alu	chr6:7250370	UTR	RREB1	1.0
ODAA	PT W8FX4W4P	Alu	chr21:46567806	UTR	DIP2A	0.726
ODE	PT GMC33B00	Alu	chr7:75740317	Promoter	HIP1	1.0
HBD	PT 6FZ9C7MC	Alu	chr4:169411142	Enhancer	NEK1	4.219E-12
Neuroblastoma	PT_58J0PB4V	SVA	chr2:227461602	Enhancer	AGFG1	NA
ODAL	PT_BPY27QQT	Alu	chr6:26028622	Enhancer	H4C2	NA
ODE	PT_KA81JM7G	Alu	chr10:89350311	Enhancer	LIPA	0.0113
SCD	PT_AXN0W87J	Alu	chr3:42059106	Enhancer	TRAK1	9.709E-05
Microtia Hispanic	PT_P6REK66H	L1	chr2:142867366	Enhancer	KYNU	NA
ES	PT_CXSMCH24	Alu	chr13:99200420	Promoter	UBAC2	0.111
Neuroblastoma	PT_7X4TQ0S0	Alu	chr2:30447127	Promoter	LCLAT1	NA
CDH	PT_W4Z36EKV	L1	chr2:33137094	Intron	LTBP1	0.526
ODAL	PT_1DAAEZYX	SVA	chr2:229907097	Intron	TRIP12	1.0
Neuroblastoma	PT_GA9F5STK	Alu	chr10:91988963	Intron	BTAF1	1.0
SCD	PT_QA254K2D	L1	chr5:39017595	Intron	RICTOR	1.0
Neuroblastoma	PT_ZPA02FW4	SVA	chr2:121483826	Intron	CLASP1	1.0
ES	PT_TGW274S6	SVA	chr2:197421627	Intron	SF3B1	1.0
SCD	PT_QA254K2D	SVA	chr3:51564902	Intron	RAD54L2	1.0
Neuroblastoma	PT_CBXEYWC5	Alu	chr4:92442143	Intron	GRID2	1.0
ODE	PT_9GBCW4SS	SVA	chr20:47589939	Intron	NCOA3	1.0
SCD	PT_EZ1E9P9V	SVA	chr4:13582834	Intron	BOD1L1	1.0
СМ	PT_V6GS089W	Alu	chr1:232535752	Intron	SIPA1L2	1.0
SCD	PT_24A962K2	L1	chr19:46381076	Intron	PPP5C	1.0

171 Table 1. Potential pathogenic *de novo* retroelement insertions identified from the GMKF cohorts.

HBD	PT_0M50Q933	Alu	chr1:176182399	Intron	RFWD2	0.999
ES	PT_SNKAQV35	Alu	chr6:1991026	Intron	GMDS	0.9983
HBD	PT_XP2CHGBB	Alu	chr12:8938247	Intron	PHC1	0.997
CDH	PT_0PN34B34	Alu	chr10:1069389	Intron	WDR37	0.997
HBD	PT_DJBYTWQ3	Alu	chr2:127881330	Intron	AMMECR1L	0.996
HBD	PT_X7GE7E9N	Alu	chr12:99293035	Intron	ANKS1B	0.993
HBD	PT_WXTBZHQG	Alu	chr6:110147613	Intron	WASF1	0.914

172

- pLI: The probability of loss-of-function intolerance
- 173 174 CDH: Congenital Diaphragmatic Hernia
- 175 176 ODE: Orofacial Defect European
- SCD: Syndromic Cranial Dysinnervation CCBD: Childhood Cancer Birth Defects 177

178 ES: Ewing Sarcoma

- 179 ODAA: Orofacial Defect African and Asian
- 180 ODAL: Orofacial Defect African Latin
- 181 CM: Craniofacial Microsomia
- 182 HBD: Heart and Other Birth Defects

183 Mosaic and parental origin of *de novo* retroelements

184 Although *de novo* retroelement insertions refer to those identified in the proband but not in the 185 parents, two types of retroelement insertions are identified as *de novo* in practice. One type is a 186 mosaic insertion in a parent that appears in the child as a germline insertion. The other type is a 187 mosaic insertion that occurs in the early development of a proband, with VAF that depends on 188 the timing of the event. As large cohort studies usually have blood or saliva samples with 189 standard depth (~30X) WGS, only very early embryonic mosaic mutations whose prevalence 190 across tissues is high enough are identified. Earlier trio-based studies on SNVs with \sim 30-40X 191 WGS have shown that besides the ~100 germline *de novo* small mutations (Jónsson et al. 2017; 192 Kong et al. 2012), a small number of proband mosaic mutations were identified (Byrska-Bishop 193 et al. 2022; Ng et al. 2021). Similarly for *de novo* retroelements, we identified variants of both 194 germline and proband mosaic origin.

195

VAF calculation for retroelement insertions is more challenging compared to SNVs/indels
because bias will be introduced when aligning the reads containing repetitive sequences (Fig.
S1). We optimized our procedure for retroelements VAF estimation (see Method for details) and
calculated the VAF for each of the identified 162, 46, and 144 DNRTs in the GMKF, 1KGP, and
ASD cohorts, respectively (Fig. 3a). Note that the VAFs previously reported for the ASD
DNRTs (separated by probands and siblings) (Borges-Monroy et al. 2021) used an earlier
version of xTea, and they have now been recalculated with the latest version of xTea.

In the VAF density plot (Fig. 3a), we observed two peaks for GMKF and 1KGP, indicating the

205 existence of germline and mosaic DNRTs in the proband. Using a gaussian mixture model to

separate the two event classes, we identified 20 (out of 162) and 8 (out of 46) mosaic DNRTs for

207	the GMKF and 1KGP cohorts, respectively (Fig. 3b). We found mosaic DNRTs for all three
208	types of TE insertions (8 Alu, 5 L1, and 7 SVA for GMKF and 2, 4, 2 for 1KGP, respectively;
209	Fig. 1c). The prevalence of mosaic DNRTs in 1KGP (17%) could be explained by somatic
210	DNTRs occurring in cell culture. Indeed, a higher mosaic rate for SNP/Indel has been reported
211	on the same data, attributed to ongoing mutation processes in cell culture (Byrska-Bishop et al.
212	2022; Ng et al. 2021). As a comparison, the mosaic DNRTs in GMKF was 12%, likely due to
213	early embryonic events. This result is consistent with an independent study on normal colon that
214	identified one mosaic L1 insertion occurring at the fourth cell division (Nam et al. 2022).
215	
216	For the 142 (out of 162) and 38 (out of 46) germline DNRTs in GMKF and 1KGP respectively,
217	we ran trio-based phasing using nearby heterozygous SNPs (see Method for details) to determine
218	their parental origins. Limited by the read length and insert size of the sequencing libraries, we
219	were only able to phase only 26 out of 142 GMKF DNRTs and 13 out of 38 1KGP DNRTs (Fig.
220	3d). Nonetheless, our inspection of the phased DNRTs by repeat type revealed a significant
221	enrichment (p=0.019; binomial test) for Alu DNRTs of paternal origin in the GMKF cohort while
222	no statistical significance was reached for L1 and SVA (Fig. 3e). A similar trend was also
223	observed in the 1KGP cohort, although it was not statistic significant due to small sample size
224	(Fig. 3e). A similar pattern was also reported in an earlier study on large pedigree data of three
225	generations (Feusier et al. 2019). Based on these results, we hypothesize that the Alu insertion
226	rate is higher in the cell types involved in spermatogenesis compared to oocytes.



Fig. 3: VAF characterization and trio-based phasing of *de novo* retroelements. a The

variation allele frequency (VAF) for the *de novo* retroelements identified in this study (162 from
GMKF and 46 from 1KGP), as well as the 144 (76 from proband and 68 from sibling) reported *de novo* retroelements from the ASD study (Borges-Monroy et al. 2021). The two peaks in
density plots of GMKF and 1KGP cohorts indicate the presence of mosaic retroelements in

- 233 proband. **b** Gaussian mixture model separation of germline and mosaic *de novo* retroelements
- based on the density of VAF. Out of the 162 and 46 *de novo* retroelements, 20 and 8 mosaic ones
- were identified for the GMKF and 1KGP respectively. **c** We checked the repeat types of the
- mosaic events. 8 *Alu*, 5 L1, and 7 SVA were annotated for the 20 GMKF mosaic retroelements,
 and 2 *Alu*, 4 L1, and 2 SVA were annotated for the 1KGP mosaic ones. d For the germline *de*
- *novo* retroelements, we applied a trio-based phasing step and identified 26 (out of 142) and 13
- 239 (out of 38) phasable ones for the GMKF and 1KGP respectively. **e** Further checking the phased
- 240 ones from the GMKF cohorts, we found more *de novo Alu* insertions were transmitted from
- father than from mother (p-value=0.019, exact binomial test), while for L1 and SVA it is unclear.
- 242 The same pattern was observed from the 1KGP data, although not statistically significant due to
- the sample size being small.
- 244

246 De novo rate estimation and enrichment of deleterious retroelements

247 The large number of trios allowed us to estimate the *de novo* rate of the retroelements in the birth 248 defect cohorts. Previous estimates were highly variable (Borges-Monrov et al. 2021), with our 249 recent study on the Simons Simplex Collection (SSC) of ASD cases (2,288 families with 250 proband and siblings) using an earlier version of xTea giving 1/26 birth (adjusted to 1/21 after 251 considering detection sensitivity benchmarked from long reads). Below, we computed the exact 252 binomial confidence intervals on all the GMKF cohorts combined as well as for four disease 253 groups that have sufficient sample sizes: Congenital Heart Defect (CHD), Congenital 254 Diaphragmatic Hernia (CDH), Orofacial Defect, and Pediatric Tumor. The Orofacial Defect 255 group consists of 3 cohorts (phs001997, phs001420, and phs001168 in Fig. 1b) of the same 256 defect but from different populations. The Pediatric Tumor group consists of 4 cohorts 257 (phs001683, phs001228, phs001846, and phs001436 in Fig. 1b) of different tumor types. For 258 reference, we list the de novo insertions for two earlier studies on the SSC ASD (Tab. S3), 1KG 259 (Tab. S4), and the Utah Centre d'Etude du Polymorphisme Humain (CEPH) cohorts (Tab. S5). 260 261 The *de novo* retroelement rate by repeat type are shown in Fig. 4a for the different cohorts. The 262 rate of all the GMKF cohorts is around 1/34 (1 per 34 births) for Alu, 1/108 for L1, and 1/93 for 263 SVA, and 1/20 for all 3 TE types combined. Compared to the ASD cohort, we observed a similar 264 rate (1/34 vs. 1/35) for Alu insertions, but much higher rate (1/108 vs. 1/189) for L1 and (1/93 vs. 1/189)265 1/244) SVA insertions. Our results are consistent with a previous study (Deciphering 266 Developmental Disorders Study 2017) that showed a higher rate for *de novo* SNVs/indels in the 267 DDD cohort compared to the ASD cohort.

268

269 Given the higher rate of insertions in the GMKF cohorts, we examined whether the DNRTs are 270 enriched in genes likely to be intolerant of loss of function (LoF), as determined by the pLI score 271 (Lek et al. 2016) and whether they enriched in exonic regions. We first simulated the distribution 272 of DNRTs across the genome with the following idea. When L1 insertions (also for Alu and SVA 273 as they rely on the L1 protein) are integrated into the genome, they prefer specific motifs 274 (consensus TTTTT/AA). Inspired by the landmark experimental study on L1 endonuclease 275 activity (Flasch et al. 2019) that engineered L1 insertions in cultured cell lines to characterize the 276 pattern of the cleavage sites, we simulated the insertion sites based on the frequency of cleavage 277 motif sequences. A key step here is to construct the weight matrix based on the frequency of the 278 cleavage motifs. We calculated the frequency from germline insertions, different from the 279 experimental study (Flasch et al. 2019) that inferred the matrix from engineered somatic 280 insertions, but the logo plots of cleavage site sequences were almost identical (Fig. S2; see 281 Method for details on the simulation procedure). Compared to the background distribution 282 generated from 10,000 simulations, we observed an enrichment (p=0.022) for *de novo* SVA 283 insertions in the high pLI (>0.9) genes, but not for Alu and L1. We also find an enrichment of de 284 novo Alu (p=0.017) and SVA (p=0.016) insertions in the exons, but no statistical significance for 285 de novo L1 insertions (Fig. 4b). Both analyses suggest that de novo retrotransposons—especially 286 *de novo* SVA insertions—found in the birth defect cohorts are more likely to be deleterious. 287



288

289 Fig. 4: De novo rate and enrichment analysis of retroelements. a We calculated the de novo 290 rate and 95% confidence interval using an exact binomial confidence interval estimate with 291 x=number of retroelements and N=number of births. ASD and CEPH are from two previous 292 studies and the rest are from the GMKF cohorts in this study. GMKF is for all the 12 cohorts, 293 "Orofacial Defect" is combined from 3 orofacial defect cohorts (phs001997, phs001420, and 294 phs001168), and "Childhood Cancer" is combined from 4 cancer related cohorts (phs001683, 295 phs001228, phs001846, and phs001436). The *de novo* rate for L1 and SVA in this study is clearly higher than ASD, with a similar rate for Alu. b We checked whether the identified de 296 297 novo retroelements from the GMKF cohorts were enriched in genes whose pLI>0.9 (top) or 298 enriched in exonic regions (bottom). We ran 10,000 simulations (details in Method) for Alu, L1 299 and SVA, and compared with the number of observed ones. There is a statistically significant enrichment of SVA insertions fallen in genes with pLI>0.9. Both Alu and SVA insertions were 300 301 also found enriched in exonic regions.

303 De novo processed pseudogene insertion and de novo TE insertion activity

304 Although germline and somatic PPG insertions in human have been reported (Esnault et al. 305 2000; Feng and Li 2021; Schrider et al. 2013; Ewing et al. 2013; Cooke et al. 2014), de novo 306 PPG insertions have not been well characterized due to their low de novo rate and the lack of 307 detection tools designed for PPGs. The study on the DDD cohort reported 2 de novo PPG 308 insertions from 9,738 WES trios (Gardner et al. 2019). Here, we extended our xTea method for 309 de novo PPG insertion detection and identified 2 de novo PPG insertions from 3,244 trios (Fig. 310 S4), suggestive of a 3-fold increase in insertion rates. One insertion originated from gene 311 HNRNPM and reverse-transcribed into a truncated PPG insertion within the intronic region of 312 FBXL7. The other originated from gene ZNF664 and mobilized to an intergenic region on 313 chromosome 2 (Fig. 5a; S4).

314

315 For L1 and SVA, the flanking regions (mainly 3' for L1, and 5' and 3' for SVA) sometimes 316 transpose together with the retrotransposon to form transductions (TDs). Because most of the TD 317 sequences are unique in the genome, they could be used to trace the source elements of the 318 insertions. We ran xTea on all the proband cases having *de novo* L1 and SVA insertions and 319 identified 4, 1, 1, and 1 transduction from GMKF, 1KGP, ASD and CEPH cohort, respectively. 320 In the original CEPH paper (Feusier et al. 2019), the authors reported 3 L1 TDs, but after manual 321 inspection, we could only confirm one of them. Our results indicate a small number of active de 322 novo transduction events.

323

324 Finally, we investigated the activity of *de novo* insertions for SVA, one of the youngest

325 retrotransposons in the human genome. SVA_E and SVA_F subfamilies are the known major

- active subfamilies (Wang et al. 2005; Hancks and Kazazian 2010); SVA F has two subfamilies,
- 327 SVA F1 and CH10 SVA F, that fused with part of *MAST2* to form new structure and transpose.
- 328 CH10_SVA_F has two *Alu* copies at the two ends, making the annotation from short reads
- 329 difficult; thus, the activity of CH10 SVA F is not explored here. SVA F1 insertions can have
- reads on one side that cover the MAST2 region and reads on the other sides aligned to the SVA_F
- 331 region, thus allowing for annotation. Using an SVA annotation module we recently developed
- 332 (Chu et al. 2023), we examined each of the *de novo* SVA insertions from the ASD (n=17), CEPH
- 333 (n=7), GMKF (n=35), and 1KGP (n=8) study (Fig. 5b) and found that SVA_E (25/58; 9 could
- not be classified) and SVA F1 (20/58) are the two most active SVA subfamilies in human
- 335 genome.



Fig. 5: Activity of *de novo* **retroelements. a** 4 L1 transductions, 3 SVA transductions, and 2

338 pseudogene insertions were identified. Each arrow points from the source elements to the

insertion site. Specifically, the 2 pseudogene insertions were originated from gene HNRNPM and

340 gene ZNF664, with HNRNPM insertion is truncated while the ZNF664 one is of full length. **b**

341 For all the *de novo* SVA retrotransposon insertions identified from the four studies (17 ASD, 7

342 CEPH, 35 GMKF and 8 1KGP), we further checked the subfamilies of each insertion. 3, 1, 5

343 were not well annotated from ASD, CEPH, and GMKF respectively. Out of those well annotated

344 ones, SVA_F1 (20/58) and SVA_E (25/58) are the most active subfamilies.

346 **DISCUSSION**

With a systematic analysis of the 12 GMKF WGS cohorts, our results revealed the different pathogenic roles DNRTs may have in causing birth defects and childhood cancers. Our study highlights the importance of WGS in identifying causal mutations beyond the standard variant types and the effectiveness of the improved xTea pipeline we developed for characterizing DNRTs in large cohort analyses and disease diagnosis.

352

353 Compared to germline DNRTs, mosaic DNRTs occurring in the proband are substantially more 354 difficult to identify due to their low VAFs. Our analysis found a set of DNRTs with low VAFs, 355 with a peak around 25% in the VAF density plot for GMKF. Although they could be variations 356 in read sampling or germline DNRTs in an uploid regions, we suspect that at least some of them 357 are mosaic variants that occurred very early in embryonic development. A peak at the similar 358 VAF (~20%) was observed for 1KGP but those are likely to be somatic variants that arose in 359 cell culture; for ASD cohorts, no such peaks were found, increasing the likelihood that the peak 360 in the GMKF cohort may be due to mosaic variants. A further analysis on other types of 361 mutations (especially de novo SNP/Indels) or sequencing data with higher coverage may provide 362 additional information for the prevalence of mosaic mutations.

363

Strong support for the functional importance of *de novo* SVA insertions came from their enrichment in genes that are estimated to be intolerant to loss of function (pLI>0.9) as well as exonic enrichment for *de novo* SVA and *Alu* insertions. We also identified several cases in which DNRTs disrupted genes that are associated with the disease in the literature. Most notable are the *Alu*-promoted deletion and an exonic insertion on the *NF1* gene. Together with the earlier studies (Wallace et al. 1991; Vogt et al. 2014; Wimmer et al. 2011) on retroelements on *NF1* gene, our

study indicates a hot spot for RTs on the *NF1* gene. For other cases, experimental validation is
needed to ascertain whether those candidate DNRTs are causative of the observed phenotypes.

373 Most studies on retroelement insertions have focused on germline L1 and Alu insertions, as they 374 are the easiest to identify due to their relatively simple structure. SVA are substantially more 375 complicated in its structure, especially with the VNTR (variable number of tandem repeats) 376 region in the middle often causing mis-annotation, as revealed in our recent work on SVA 377 detection and annotation (Chu et al. 2023). The increasing adaption of long-read sequencing 378 platforms will greatly enhance detection sensitivity and specificity, as well as expanding the 379 regions of the genome that can be interrogated. The GMKF cohort continues to increase in size, 380 as do numerous other WGS studies for various genetic diseases. The resulting datasets will 381 enable discovery of additional disease-associated genes, allow for more accurate inferences on 382 the rates of mosaic insertion events, help pinpoint active source elements through transduction 383 events, and shed light on the expanding role that retroelements play in disease initiation. 384

385 METHOD

386 De novo retroelements identification from trio data

387 Compared to germline retroelement insertions, DNRTs are rare, thus sensitivity is important for 388 identification. Here, we optimized our xTea method for DNRT insertion identification. Fig. 1a 389 shows the major steps: for one given trio data, (i) we ran xTea germline module on the proband 390 sample (by default with parameters "--nclip 2 --cr 0 --nd 3 --nfclip 2 --nfdisc 3"); (ii) we ran 391 xTea somatic module on the candidates generated from step (i) with alignments from both 392 parents as controls; *(iii)* we further developed a machine learning based filtering module 393 (manuscript in preparation) to filter out the false positives. For each candidate insertion, we 394 converted the alignments to images using BamSnap (Kwon et al. 2021), where each candidate is 395 composed of three images from the trio on the same location. We first prepared a positive 396 training set from semi-simulated data, where we selected germline heterozygous retroelements 397 from one sample and viewed it as the "proband", and then we selected two unrelated samples 398 that do not have retroelement insertions on this location as the "parents". From these three 399 "combined" samples on this location we generated one positive image. In this way, we prepared 400 6952 positive training images. Then we prepared the same number of negative training images 401 from xTea output on two cohorts (phs001228 and phs001168) that we had manually inspected 402 for the true positives. Next, we trained a model from the positive and negative training sets. 403 Then, for each candidate image, we predict it to true positive or false positive; (iv) lastly, we ran 404 manual inspection on each of the candidates to select the true positive variants.

405

406 De novo retroelements annotation

407 For each identified DNRT, we first annotated it as exonic, 5' UTR, 3' UTR, intronic, or

408 intergenic based on the GENCODE (v28 on GRCh38) gene annotation file. Then, we ran

409	ANNOVAR (version downloaded on May 2022) to annotate DNRTs fall in promoter and
410	enhancer regions. We used the pLI score from the ExAC study (Lek et al. 2016) to annotate the
411	estimated intolerance of each gene to mutations, and pLI>0.9 are annotated as "high intolerant".
412	
413	In addition, we also ran subfamily annotation specifically for <i>de novo</i> SVA insertions, because
414	the active subfamilies are less well characterized in large cohorts. To annotate the SVA insertion
415	subfamilies, we first collected all the discordant and clipped reads originated from the insertion.
416	Then we ran local assembly on the collected reads using the xTea assembly module. Next, we
417	ran the SVA annotation module (initially developed for a different study whose manuscript in
418	review) on the assembled sequences to get the subfamily information of each de novo SVA
419	insertion. Insertions annotated to more than one subfamily or failed to be assembled were
420	annotated as "uncertain".
421	

422 Variation allele frequency (VAF) calculation

423 Different from SNV VAF estimated by calculating the ratio between the number of reads 424 containing the mutation and the total number of reads at the site, calculating VAF for DNRTs is 425 more challenging. We illustrate the major biases introduced due to reads alignments in Fig. S1. 426 Generally, for one clipped read with part of the read from the retroelements and the other part 427 from the flanking regions, if the length of the retroelement part is short (by default, BWA mem 428 has a minimum kmer length of 19), then the read will be aligned elsewhere as the unique part 429 (part from flanking region) is short, as a result, these reads will not be counted when calculating 430 the VAF. To correct the introduced bias, when counting the number of full mapped reads 431 covering the breakpoint, we skipped reads having short overlap (by default <19) with the 432 flanking region. In addition to calculate VAF from reads covering the breakpoint, discordant

pairs can also be used for calculating the VAF. Basically, within the given range (by default,
insert-size) we count the number of discordant pairs and concordant pairs, and then calculate the
VAF. In Fig. S1, we show the calculated clip- and discordant-based VAFs for 115,115 germline
TE insertions. In practice, we took the average of the clip- and discordant-based VAF as the
VAF of each DNRT.

438

439 Trio based phasing

440 For some of the identified DNRTs, we can phase them to derive paternal or maternal origin 441 based on the nearby heterozygous SNVs. For example, if we find heterozygous SNVs in the 442 father and identify the same SNVs within the discordant pairs of the DNRT in the proband, then 443 we can infer the DNRT to be of paternal origin (Fig. S3c,d). However, in practice, we can only 444 find nearby heterozygous SNVs for a small fraction of DNRTs. To broaden the range of phasable 445 DNRTs, for the germline DNRTs in proband, if we observe heterozygous SNVs in one of the 446 parents, but the same SNVs are found in the non-DNRT reads, then we can infer that the DNRT 447 is inherited from the other parent. To achieve this, we first adopt a Gaussian Mixture Model (2) 448 mixture components) to classify the DNRTs as germline or mosaic, and then phase the set of 449 germline variants. To call heterozygous SNVs from the parents, we ran samtools "mpileup" and 450 "call" on the local region of each DNRT. To call SNVs for each DNRT from the proband, we 451 first separated the reads aligned to the local region to two groups: "DNRT reads" and "non-452 DNRT reads". For each group, we ran samtools "mpileup" and "call" to identify the SNVs. In 453 addition, we also ran manual inspection for each phased DNRTs from BamSnap screenshots to 454 further validate the phased the DNRTs. The whole pipeline is shown in Fig. S3.

455

456 *De novo* rate estimation

457 To estimate the *de novo* rate of retroelements, we adopted the exact binomial confidence interval 458 estimate, where X is the number of retroelements, and N is the number of births. To compare the 459 *de novo* rate among different disease cohorts, we show the results of "Syndromic cranial 460 dysinnervation", "Heart birth defects", "Orofacial birth defects", "childhood cancer", where 461 "Orofacial birth defects" results are merged from three orofacial birth defects of different 462 populations (phs001168, phs001420, and phs001997), and the "childhood cancer" results are 463 merged from the four tumor cohorts (phs001436, phs001228, phs001683, and phs001846). In 464 addition, we also compared the overall *de novo* rate in the birth defect disorders with two earlier 465 studies on autism (Borges-Monroy et al. 2021) and large pedigree of normal samples (Feusier et 466 al. 2019), where we used the number of *de novo* retroelements and the number of births in their 467 released results.

468

469 *De novo* retroelements enrichment analysis

470 To test whether the identified DNRTs are enriched in the GMKF data or not, we need a control 471 model that simulates the random hits of DNRTs. However, it is known that RTs are not purely 472 randomly happened on the genome. A recent study based on engineered L1s in cell lines inferred 473 that there are specific endonuclease (EN) cleavage motifs (Flasch et al. 2019). Here, we adopt 474 the similar approach to build the control model as described in the endonuclease activity study 475 from engineered L1s (Flasch et al. 2019). As shown in Fig. S2, we first gather all the possible 476 EN cleavage motifs, then for each motif we estimate its frequency, which later will be used as 477 the probability of a simulated insertion occurring with the motif. Differently, here we use 478 germline insertion rather than engineered *de novo* L1s to gather all the possible motifs. To 479 achieve this, we first ran xTea on the 1KGP high depth WGSs and collect the high-quality TE 480 insertions (labeled with "tprt both" in xTea output indicating exist of both the TSD and polyA

481 tail; and require the population AF > 0.01). For each TE insertion, we collect the first left 4 bases 482 and the right 3 bases at the breakpoint (adjusted accordingly for antisense cases). Then, we put 483 all the collected motifs in a table and calculate the frequency for each one. We also adopt the 484 same approach as described in the mentioned study (Flasch et al. 2019) to include potential motif 485 not recruited in the motif table: We split the 7-base motif to 3 independent segments: first 2 486 bases, middle 4 bases and the last base. For each segment, we calculate the frequency of each 487 sub-motif based on the frequency of the 7-base motifs. In this way, we have 3 tables of sub-488 motifs whose frequency have been calculated. Thus, to generate a 7-base motif, we generate the 489 3 segments separately and for each segment we select a sub-motif based on the frequency table. 490 Then, we merge the 3 segments to one 7-base motif. Now, given one motif, we need to find out 491 where on the genome this motif can be generated. To achieve this, we build another 7-base motif 492 table for the whole genome, where we save all the positions of each motif. In this way, once 493 given a motif, we randomly select one from all the positions.

494

To construct the control model, for each round we simulated the same 163 DNRTs with our pipeline, and we repeated the experiments for 10,000 times. We did enrichment analysis for insertions fallen in exon regions and in pLI high (>0.9) genes separately.

499 Data availability

- 500 The 12 cohorts of pediatric whole genome sequencing (WGS) data were accessed through the
- 501 portal of Gabriella Miller Kids First Pediatric Research Program https://portal.kidsfirstdrc.org/.
- 502 The high depth trio based WGS data from the 1000 Genomes Project were downloaded from the
- 503 International Genome Sample Resource (IGSR) at https://www.internationalgenome.org/data/.

504

505 Code availability

- 506 Source code for the de novo retroelements identification is available at
- 507 https://github.com/parklab/xTea (doi:10.5281/zenodo.4743788).

Borges-Monroy, Rebeca, Chong Chu, Caroline Dias, Jaejoon Choi, Soohyun Lee, Yue Gao,

509 **REFERENCES**

510

511 Taehwan Shin, Peter J. Park, Christopher A. Walsh, and Eunjung Alice Lee. 2021. "Whole-512 Genome Analysis Reveals the Contribution of Non-Coding de Novo Transposon Insertions 513 to Autism Spectrum Disorder." Mobile DNA 12 (1): 28. 514 Brandler, William M., Danny Antaki, Madhusudan Guiral, Morgan L. Kleiber, Joe Whitney, 515 Michelle S. Maile, Oanh Hong, et al. 2018. "Paternally Inherited Cis-Regulatory Structural 516 Variants Are Associated with Autism." Science 360 (6386): 327-31. 517 Brandler, William M., Danny Antaki, Madhusudan Gujral, Amina Noor, Gabriel Rosanio, 518 Timothy R. Chapman, Daniel J. Barrera, et al. 2016. "Frequency and Complexity of De 519 Novo Structural Mutation in Autism." American Journal of Human Genetics 98 (4): 667-520 79. 521 Bultmann-Mellin, Insa, Anne Conradi, Alexandra C. Maul, Katharina Dinger, Frank Wempe, 522 Alexander P. Wohl, Thomas Imhof, et al. 2015. "Modeling Autosomal Recessive Cutis 523 Laxa Type 1C in Mice Reveals Distinct Functions for Ltbp-4 Isoforms." Disease Models & 524 *Mechanisms* 8 (4): 403–15. 525 Burns, Kathleen H. 2017. "Transposable Elements in Cancer." Nature Reviews. Cancer 17 (7): 526 415-24. Byrska-Bishop, Marta, Uday S. Evani, Xuefang Zhao, Anna O. Basile, Haley J. Abel, Allison A. 527 528 Regier, André Corvelo, et al. 2022. "High-Coverage Whole-Genome Sequencing of the 529 Expanded 1000 Genomes Project Cohort Including 602 Trios." Cell 185 (18): 3426-40.e19. 530 Chen, Siwei, Laurent C. Francioli, Julia K. Goodrich, Ryan L. Collins, Oingbo Wang, Jessica 531 Alföldi, Nicholas A. Watts, et al. 2022. "A Genome-Wide Mutational Constraint Map 532 Quantified from Variation in 76,156 Human Genomes." bioRxiv. 533 https://doi.org/10.1101/2022.03.20.485034. 534 Chu, Chong, Rebeca Borges-Monroy, Vinayak V. Viswanadham, Soohyun Lee, Heng Li, 535 Eunjung Alice Lee, and Peter J. Park. 2021. "Comprehensive Identification of Transposable 536 Element Insertions Using Multiple Sequencing Technologies." Nature Communications 12 537 (1): 3836. 538 Chuong, Edward B., Nels C. Elde, and Cédric Feschotte. 2017. "Regulatory Activities of 539 Transposable Elements: From Conflicts to Benefits." Nature Reviews. Genetics 18 (2): 71-540 86. 541 Cogné, Benjamin, Sophie Ehresmann, Eliane Beauregard-Lacroix, Justine Rousseau, Thomas 542 Besnard, Thomas Garcia, Slavé Petrovski, et al. 2019. "Missense Variants in the Histone 543 Acetyltransferase Complex Component Gene TRRAP Cause Autism and Syndromic 544 Intellectual Disability." American Journal of Human Genetics 104 (3): 530-41. 545 Cooke, Susanna L., Adam Shlien, John Marshall, Christodoulos P. Pipinikas, Inigo 546 Martincorena, Jose M. C. Tubio, Yilong Li, et al. 2014. "Processed Pseudogenes Acquired 547 Somatically during Cancer Development." Nature Communications 5 (1): 1-9. 548 Esnault, Cécile, Joël Maestre, and Thierry Heidmann. 2000. "Human LINE Retrotransposons Generate Processed Pseudogenes." Nature Genetics 24 (4): 363-67. 549 550 Ewing, Adam D., Tracy J. Ballinger, Dent Earl, Broad Institute Genome Sequencing and 551 Analysis Program and Platform, Christopher C. Harris, Li Ding, Richard K. Wilson, and 552 David Haussler. 2013. "Retrotransposition of Gene Transcripts Leads to Structural 553 Variation in Mammalian Genomes." Genome Biology 14 (3): R22.

Humans and Three Great Apes Revealed by Long-Read Assemblies." Molecular Biology

Feng, Xiaowen, and Heng Li. 2021. "Higher Rates of Processed Pseudogene Acquisition in

- 556 and Evolution 38 (7): 2958-66. 557 Feusier, Julie, W. Scott Watkins, Jainy Thomas, Andrew Farrell, David J. Witherspoon, Lisa 558 Baird, Hongseok Ha, Jinchuan Xing, and Lynn B. Jorde. 2019. "Pedigree-Based Estimation 559 of Human Mobile Element Retrotransposition Rates." Genome Research 29 (10): 1567-77. 560 Flasch, Diane A., Ángela Macia, Laura Sánchez, Mats Ljungman, Sara R. Heras, José L. García-561 Pérez, Thomas E. Wilson, and John V. Moran. 2019. "Genome-Wide de Novo L1 562 Retrotransposition Connects Endonuclease Activity with Replication." Cell 177 (4): 837-563 51.e28. 564 Gardner, Eugene J., Vincent K. Lam, Daniel N. Harris, Nelson T. Chuang, Emma C. Scott, W. 565 Stephen Pittard, Ryan E. Mills, 1000 Genomes Project Consortium, and Scott E. Devine. 566 2017. "The Mobile Element Locator Tool (MELT): Population-Scale Mobile Element 567 Discovery and Biology." Genome Research 27 (11): 1916-29. 568 Gardner, Eugene J., Elena Prigmore, Giuseppe Gallone, Petr Danecek, Kaitlin E. Samocha, Juliet 569 Handsaker, Sebastian S. Gerety, et al. 2019. "Contribution of Retrotransposition to 570 Developmental Disorders." Nature Communications 10 (1): 4630. 571 Hancks, Dustin C., and Haig H. Kazazian Jr. 2010. "SVA Retrotransposons: Evolution and 572 Genetic Instability." Seminars in Cancer Biology 20 (4): 234-45. 573 Hancks, Dustin C., and Haig H. Kazazian Jr. 2016. "Roles for Retrotransposon Insertions in 574 Human Disease." Mobile DNA 7 (May): 9. 575 Jónsson, Hákon, Patrick Sulem, Birte Kehr, Snaedis Kristmundsdottir, Florian Zink, Eirikur 576 Hiartarson, Marteinn T. Hardarson, et al. 2017. "Parental Influence on Human Germline de 577 Novo Mutations in 1,548 Trios from Iceland." Nature 549 (7673): 519-22. 578 Keane, Thomas M., Kim Wong, and David J. Adams. 2013. "RetroSeq: Transposable Element 579 Discovery from next-Generation Sequencing Data." Bioinformatics 29 (3): 389-90. 580 Kong, Augustine, Michael L. Frigge, Gisli Masson, Soren Besenbacher, Patrick Sulem, Gisli 581 Magnusson, Sigurion A. Gudjonsson, et al. 2012. "Rate of de Novo Mutations and the 582 Importance of Father's Age to Disease Risk." Nature 488 (7412): 471–75. 583 Chu, Chong, Eric W. Lin, Antuan Tran, Hu Jin, Natalie I. Ho, Alexander Veit, Isidro Cortes-584 Ciriano, Kathleen H. Burns, David T. Ting, and Peter J. Park. 2023. "The Landscape of 585 Human SVA Retrotransposons." Nucleic Acids Research 51 (21): 11453-65. 586 Kwon, Minseok, Soohyun Lee, Michele Berselli, Chong Chu, and Peter J. Park. 2021. 587 "BamSnap: A Lightweight Viewer for Sequencing Reads in BAM Files." Bioinformatics, 588 January. https://doi.org/10.1093/bioinformatics/btaa1101. 589 Lee, Eunjung, Rebecca Iskow, Lixing Yang, Omer Gokcumen, Psalm Haseley, Lovelace J. 590 Luquette 3rd, Jens G. Lohr, et al. 2012. "Landscape of Somatic Retrotransposition in 591 Human Cancers." Science 337 (6097): 967-71. 592 Lek, Monkol, Konrad J. Karczewski, Eric V. Minikel, Kaitlin E. Samocha, Eric Banks, Timothy 593 Fennell, Anne H. O'Donnell-Luria, et al. 2016. "Analysis of Protein-Coding Genetic 594 Variation in 60,706 Humans." Nature 536 (7616): 285–91. 595 Machiela, Mitchell J., Thomas G. P. Grünewald, Didier Surdez, Stephanie Reynaud, Olivier 596 Mirabeau, Eric Karlins, Rebeca Alba Rubio, et al. 2018. "Genome-Wide Association Study 597 Identifies Multiple New Loci Associated with Ewing Sarcoma Susceptibility." Nature
 - *Communications* 9 (1): 3184.

554

599	Mavros, Chrystal F., Catherine A. Brownstein, Roshni Thyagrajan, Casie A. Genetti, Sahil
600	Tembulkar, Kelsey Graber, Quinn Murphy, et al. 2018. "De Novo Variant of TRRAP in a
601	Patient with Very Early Onset Psychosis in the Context of Non-Verbal Learning Disability
602	and Obsessive-Compulsive Disorder: A Case Report." BMC Medical Genetics 19 (1): 197.
603	Nam, Chang Hyun, Jeonghwan Youk, Jeong Yeon Kim, Joonoh Lim, Jung Woo Park, Soo A.
604	Oh, Hyun Jung Lee, et al. 2022. "Extensive Mosaicism by Somatic L1 Retrotransposition in
605	Normal Human Cells." <i>bioRxiv</i> . https://doi.org/10.1101/2022.05.18.492429.
606	Ng, Jeffrey K., Pankaj Vats, Elyn Fritz-Waters, Stephanie Sarkar, Eleanor I. Sams, Evin M.
607	Padhi, Zachary L. Payne, et al. 2021. "De Novo Variant Calling Identifies Cancer Mutation
608	Profiles in the 1000 Genomes Project." <i>bioRxiv</i> . https://doi.org/10.1101/2021.05.27.445979.
609	Pottie, Lore, Christin S. Adamo, Aude Beyens, Steffen Lütke, Piyanoot Tapaneeyaphan,
610	Adelbert De Clercq, Phil L. Salmon, et al. 2021. "Bi-Allelic Premature Truncating Variants
611	in LTBP1 Cause Cutis Laxa Syndrome." American Journal of Human Genetics 108 (6):
612	1095–1114.
613	Schrider, Daniel R., Fabio C. P. Navarro, Pedro A. F. Galante, Raphael B. Parmigiani, Anamaria
614	A. Camargo, Matthew W. Hahn, and Sandro J. de Souza. 2013. "Gene Copy-Number
615	Polymorphism Caused by Retrotransposition in Humans." <i>PLoS Genetics</i> 9 (1): e1003242.
616	Shi, Xianping, Yueyuan Zheng, Liling Jiang, Bo Zhou, Wei Yang, Liyan Li, Lingwen Ding, et
617	al. 2020. "EWS-FLI1 Regulates and Cooperates with Core Regulatory Circuitry in Ewing
618	Sarcoma." Nucleic Acids Research 48 (20): 11434–51.
619	Thung, Djie Tjwan, Joep de Ligt, Lisenka E. M. Vissers, Marloes Steehouwer, Mark Kroon,
620	Petra de Vries, Eline P. Slagboom, Kai Ye, Joris A. Veltman, and Jayne Y. Hehir-Kwa.
621	2014. "Mobster: Accurate Detection of Mobile Element Insertions in next Generation
622	Sequencing Data." Genome Biology 15 (10): 488.
623	Tubio, Jose M. C., Yilong Li, Young Seok Ju, Inigo Martincorena, Susanna L. Cooke, Marta
624	Tojo, Gunes Gundem, et al. 2014. "Extensive Transduction of Nonrepetitive DNA Mediated
625	by L1 Retrotransposition in Cancer Genomes." Science 345 (6196): 1251343.
626	Urban, Zsolt, and Elaine C. Davis. 2014. "Cutis Laxa: Intersection of Elastic Fiber Biogenesis,
627	TGFβ Signaling, the Secretory Pathway and Metabolism." Matrix Biology: Journal of the
628	International Society for Matrix Biology 33 (January): 16–22.
629	Vogt, Julia, Kathrin Bengesser, Kathleen B. M. Claes, Katharina Wimmer, Victor-Felix
630	Mautner, Rick van Minkelen, Eric Legius, et al. 2014. "SVA Retrotransposon Insertion-
631	Associated Deletion Represents a Novel Mutational Mechanism Underlying Large Genomic
632	Copy Number Changes with Non-Recurrent Breakpoints." Genome Biology 15 (6): R80.
633	Wang, Hui, Jinchuan Xing, Deepak Grover, Dale J. Hedges, Kyudong Han, Jerilyn A. Walker,
634	and Mark A. Batzer. 2005. "SVA Elements: A Hominid-Specific Retroposon Family."
635	Journal of Molecular Biology 354 (4): 994–1007.
636	Werling, Donna M., Harrison Brand, Joon-Yong An, Matthew R. Stone, Lingxue Zhu, Joseph T.
637	Glessner, Ryan L. Collins, et al. 2018. "An Analytical Framework for Whole-Genome
638	Sequence Association Studies and Its Implications for Autism Spectrum Disorder." Nature
639	<i>Genetics</i> 50 (5): 727–36.
640	Wimmer, Katharina, Tom Callens, Annekatrin Wernstedt, and Ludwine Messiaen. 2011. "The
641	NF1 Gene Contains Hotspots for L1 Endonuclease-Dependent de Novo Insertion." PLoS
642	<i>Genetics</i> 7 (11): e1002371.

- Kia, Wenjun, Jiongjiong Hu, Jing Ma, Jianbo Huang, Xu Wang, Nan Jiang, Jin Zhang, Zhaoxin
 Ma, and Duan Ma. 2019. "Novel TRRAP Mutation Causes Autosomal Dominant Non-
- 644 Ma, and Duan Ma. 2019. "Novel TRRAP Mutation Causes Autosomal Dor 645 Syndromic Hearing Loss." *Clinical Genetics* 96 (4): 300–308.
- Zhang, Qiang, Zailong Qin, Shang Yi, Hao Wei, Xun Zhao Zhou, and Jiasun Su. 2020. "Two
 Novel Compound Heterozygous Variants of LTBP4 in a Chinese Infant with Cutis Laxa
- Type IC and a Review of the Related Literature." *BMC Medical Genomics* 13 (1): 183.
- 649Zhuang, Jiali, Jie Wang, William Theurkauf, and Zhiping Weng. 2014. "TEMP: A
- 650 Computational Method for Analyzing Transposable Element Polymorphism in
 651 Populations." *Nucleic Acids Research* 42 (11): 6826–38.
- Deciphering Developmental Disorders Study. 2017. "Prevalence and Architecture of de Novo
 Mutations in Developmental Disorders." *Nature* 542 (7642): 433–38.
- Wallace, M. R., L. B. Andersen, A. M. Saulino, P. E. Gregory, T. W. Glover, and F. S. Collins.
- 655 1991. "A de Novo Alu Insertion Results in Neurofibromatosis Type 1." *Nature* 353 (6347):
 656 864–66.
- 657

658 Acknowledgements

- 659 This work was supported by R03CA249364 from the National Cancer Institute. VL is supported
- 660 by the Swedish Research Council (2020-00583).

661

- 662 Competing interests
- 663 The authors declare no competing interests.

664